Cargando…

Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer

PURPOSE: The pro vision of clinically assisted nutrition (CAN) in patients with advanced cancer is controversial, and there is a paucity of specific guidance, and so a diversity in clinical practice. Consequently, the Palliative Care Study Group of the Multinational Association of Supportive Care in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alderman, Bryony, Allan, Lindsey, Amano, Koji, Bouleuc, Carole, Davis, Mellar, Lister-Flynn, Stephanie, Mukhopadhyay, Sandip, Davies, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857106/
https://www.ncbi.nlm.nih.gov/pubmed/34665311
http://dx.doi.org/10.1007/s00520-021-06613-y
Descripción
Sumario:PURPOSE: The pro vision of clinically assisted nutrition (CAN) in patients with advanced cancer is controversial, and there is a paucity of specific guidance, and so a diversity in clinical practice. Consequently, the Palliative Care Study Group of the Multinational Association of Supportive Care in Cancer (MASCC) formed a Subgroup to develop evidence-based guidance on the use CAN in patients with advanced cancer. METHODS: This guidance was developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials respectively. The outcomes of the review were categorised by the level of evidence, and a “category of guideline” based on the level of evidence (i.e. “recommendation”, “suggestion”, or “no guideline possible”). RESULTS: The Subgroup produced 11 suggestions, and 1 recommendation (due to the paucity of evidence). These outcomes relate to assessment of patients, indications for CAN, contraindications for CAN, procedures for initiating CAN, and re-assessment of patients. CONCLUSIONS: This guidance provides a framework for the use of CAN in advanced cancer, although every patient needs individualised management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-021-06613-y.